Matthew C. Johnson

Matthew C. Johnson

Auto-generated profile, based on publicly available information

Matthew C. Johnson

Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2019 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Open access
PDF file
MJMatthew C. Johnson
Matthew C. Johnson
APAdrian Pona
Adrian Pona
AAAdrienne L. Adler-Neal
Adrienne L. Adler-Neal
CKChelsea Kesty
Chelsea Kesty
ACAbigail Cline
Abigail Cline
SFSteven R. Feldman
Steven R. Feldman
Treatment of childhood atopic dermatitis (AD) is hindered by nonadherence, but caregiver reassurance may help overcome this hurdle. To assess caregivers’ willingness to treat childhood AD with a corticosteroid when presented with clinical trial evidence, anecdote, or both. A total of 476 caregivers were recruited through a dermatology clinic and online crowdsourcing platform. Subjects were randomized to receive clinical trial evidence, anecdote, or both, using either the term “medication” or “topical steroid.” Additional caregivers were queried about their willingness to treat with the doctor’s recommendation or without knowledge of its safety information. Responses were recorded on a 10-point Likert scale. Caregivers’ willingness to treat was higher in all information assignment groups compared to those not provided with safety information: clinical trial evidence of a “medication” (P = .003; Cohen’s d = 0.83) or “topical steroid” (P = .030; d = 0.55), anecdote of a “medication” (P < .0001; d = 1.37) or “topical steroid” (P < .0001; d = 0.85), both clinical trial evidence and anecdote of a “medication” (P < .0001; d = 1.00) or “topical steroid” (P = .000; d = 0.89), and simply the doctor’s recommendation (P < .0001; d = 0.92). Significance was corrected for multiple comparisons to 0.0018. There were no differences between caregivers of children with and without AD (P = .36). Providing anecdotal reassurance, even in the setting of reported high willingness to treat with the doctor’s recommendation, may be an effective strategy to improve caregivers’ perceptions of starting new medications.

2 March 2021 in Journal of Psoriasis and Psoriatic Arthritis®
Verified
Journal Article
Closed access
PDF file
MJMatthew C. Johnson
Matthew C. Johnson
CHCourtney E. Heron
Courtney E. Heron
RGRima I. Ghamrawi
Rima I. Ghamrawi
EBEsther A. Balogh
Esther A. Balogh
SFSteven R. Feldman
Steven R. Feldman
Background: Clinical trials often focus on the efficacy of biologic agents in the treatment of psoriasis without emphasis on the speed of response. Objective: We evaluated clinical trial data to determine which biologic agents achieve the fastest treatment response. Methods: A review of phase III clinical trials of biologic agents in psoriasis was performed. Speed was determined by analyzing Psoriasis Area and Severity Index (PASI) 75/90 responder curves to estimate the point at which 50% of subjects achieved that outcome, PASI 75/9050. Time to achieve PASI 75/9050 was averaged across trials. Results: Time to achieve PASI 7550, in weeks: brodalumab 210 mg, 3.5; ixekizumab 80 mg Q2 W, 4; secukinumab 300 mg, 5; infliximab 5mg/kg, 5.5; risankizumab 150 mg, 6; guselkumab 100 mg, 6.25; adalimumab 40 mg, 7.25; ustekinumab 45/90 mg, 7.4; certolizumab 400 mg, 7.5; tildrakizumab 100 mg, 9; etanercept 50 mg, 12.5. PASI 9050 responder rate estimations revealed a similar trend. Conclusion: Interleukin-17 inhibitors have a more rapid treatment response compared with other classes. Although speed is important, efficacy, persistence, side effects, cost of treatment, and number of injections are all factors to consider.

3 December 2018 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
ZCZachary A. Curry
Zachary A. Curry
MJMatthew C. Johnson
Matthew C. Johnson
EUEmily L. Unrue
Emily L. Unrue
Steven R. FeldmanSteven R. Feldman
Steven R. Feldman
Background: Caregivers are often apprehensive about treating their child’s atopic dermatitis with a topical corticosteroid. Typical concerns include anxiety regarding side effects and the perceived burden of treatment. The perception of burden may be modifiable through anchoring. Objective: To evaluate caregivers’ willingness to treat their child’s atopic dermatitis with a topical corticosteroid once-daily if initially anchored to the idea of a four-times-daily treatment regimen. Methods: A prospective survey study was performed in 100 caregivers of children with atopic dermatitis. Scores were treated as ordinal data and evaluated using the Mann-Whitney U test and chi-squared test. Results: Of the 100 recruited participants, 97 were eligible and returned completed surveys. Subjects anchored to a four-times-daily treatment regimen were more willing to treat their child’s atopic dermatitis once-daily (mean, 8.7) than those not anchored (mean, 7.9), however the difference between these groups was not statistically significant (P = 0.173). Conclusions: Caregivers reported being generally quite willing to apply topical corticosteroids once-daily. Anchoring was associated with a slightly higher score, though it was not statistically significant. For most patients with atopic dermatitis, anchoring may not be helpful, but for patients whose main barrier is perceived burdensomeness of treatment, anchoring may be of some benefit.

27 January 2021 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
PDF file
MJMatthew C. Johnson
Matthew C. Johnson
CHCourtney E. Heron
Courtney E. Heron
SFSteven R. Feldman
Steven R. Feldman

1 November 2016 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
RDR.M. Downs
R.M. Downs
MHM.A. Hughes
M.A. Hughes
SKS.T. Kinsey
S.T. Kinsey
MJM.C. Johnson
M.C. Johnson
BBB.L. Baumgarner
B.L. Baumgarner

1 August 2020 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
JBJeremy K. Bray
Jeremy K. Bray
MJMatthew C. Johnson
Matthew C. Johnson
EME.J. Masicampo
E.J. Masicampo
Steven R. FeldmanSteven R. Feldman
Steven R. Feldman